Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 4,982 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Hepatocellular Carcinoma
Interventions: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more

Conditions: Pulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 44
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Lenalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 70
States / cities: Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 57 more

Conditions: Leukemia
Interventions: ara-C, Daunorubicin, Etoposide, PSC-833, Aldesleukin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 59 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 33
States / cities: La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more

Conditions: PTSD
Interventions: Trauma Informed Guilt Reduction Therapy, Cognitive Processing Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Diego, California • Tampa, Florida

Conditions: Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections, Pregnancy Complications, Infectious
Interventions: Adherence assessment; Behavioral
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 14 Years and older · Female only
Enrollment: 3,090 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 64 Years
Enrollment: 4,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more

Conditions: Lymphoma, HIV
Interventions: Autologous transplant, BCNU, Etoposide, Cytarabine, Melphalan; Procedure · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 15 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 16
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 10 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Nivolumab; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 331
States / cities: Birmingham, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 220 more

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: Placebo, Ravulizumab; Drug · Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more

Conditions: Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: glucarpidase; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 88
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Chronic Pain
Interventions: Spinal Cord Stimulation System; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 20
States / cities: La Mesa, California • Orange, California • Wilmington, Delaware + 17 more

Conditions: Cystic Fibrosis (CF), New Diagnostics
Interventions: Not listed
Lead sponsor: Chris Goss; Other
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: La Jolla, California • Minneapolis, Minnesota • St Louis, Missouri + 6 more

Conditions: Autism
Interventions: Behavioral Interventions for Anxiety in Children with Autism (BIACA), Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Years to 14 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Culver City, California • Sacramento, California • San Diego, California

Conditions: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Atezolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Santa Monica, California + 9 more

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 21 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 21 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Placebo, BFKB8488A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 39
States / cities: Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 30 more

Conditions: Prader-Willi Syndrome, Hyperphagia
Interventions: Livoletide, Placebo; Drug
Lead sponsor: Millendo Therapeutics SAS; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 12 more

Conditions: Veno-occlusive Disease
Interventions: Defibrotide, Best Supportive Care; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Posttraumatic Stress Disorder
Interventions: losartan, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: La Jolla, California • Washington D.C., District of Columbia • Bethesda, Maryland + 3 more

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more

Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more

Conditions: Parkinson Disease
Interventions: DaTscan; Drug
Lead sponsor: Ken Marek, MD; Other
Eligibility: 30 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more

Search by objective public record fields.

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

Non-Inferiority Trial of TrIGR for PTSD

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Autologous Transplant in HIV Patients (BMT CTN 0803)

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

CBT for Youth With Autism and Emotional/Behavioral Needs in Community Care Settings

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

A Controlled Trial of Losartan in Posttraumatic Stress Disorder

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression